Aclaris Therapeutics, Inc.
ACRS
$6.18
$0.162.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -51.05% | -52.94% | -58.20% | -41.87% | -47.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.05% | -52.94% | -58.20% | -41.87% | -47.56% |
| Cost of Revenue | 32.78% | 27.38% | 22.19% | -2.22% | -37.74% |
| Gross Profit | -71.55% | -71.07% | -71.83% | -28.90% | 31.84% |
| SG&A Expenses | 5.00% | 5.01% | -1.04% | -13.08% | -14.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.61% | 20.70% | 14.95% | -5.32% | -32.40% |
| Operating Income | -46.34% | -44.86% | -41.03% | -11.44% | 26.28% |
| Income Before Tax | 43.75% | 46.50% | 50.84% | -279.12% | -128.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.75% | 46.50% | 50.84% | -282.88% | -129.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.75% | 46.50% | 50.84% | -282.88% | -129.47% |
| EBIT | -46.34% | -44.86% | -41.03% | -11.44% | 26.28% |
| EBITDA | -46.75% | -45.28% | -41.71% | -12.00% | 26.10% |
| EPS Basic | 57.24% | 59.88% | 64.96% | -165.78% | -65.55% |
| Normalized Basic EPS | -30.32% | -12.84% | 8.80% | 33.67% | 55.54% |
| EPS Diluted | 57.24% | 59.88% | 64.96% | -165.78% | -65.55% |
| Normalized Diluted EPS | -30.32% | -12.84% | 8.80% | 33.67% | 55.54% |
| Average Basic Shares Outstanding | 25.55% | 37.82% | 58.63% | 62.64% | 44.93% |
| Average Diluted Shares Outstanding | 25.55% | 37.82% | 58.63% | 62.64% | 44.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |